<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00208702</url>
  </required_header>
  <id_info>
    <org_study_id>0431-1996</org_study_id>
    <secondary_id>R01MH056946</secondary_id>
    <secondary_id>431-1996</secondary_id>
    <secondary_id>DSIR AT-SO</secondary_id>
    <nct_id>NCT00208702</nct_id>
  </id_info>
  <brief_title>Thyroid Medication and Antidepressants for Treating Major Depression</brief_title>
  <official_title>Thyroid Axis in Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of treatment with supplemental triiodothyronine
      (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in
      improving symptoms of major depressive disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is that triiodothyronine (Cytomel) supplementation of the
      antidepressant sertraline (Zoloft) will result in a greater improvement in HAM-D scores
      compared to placebo in the treatment of Major Depressive Disorder (MDD).

      The goals of this proposal are to examine the relationship between Major Depressive Disorder
      (MDD) and abnormalities of the hypothalamic pituitary thyroid (HPT) axis. This protocol will
      systematically examine the value of supplemental triiodothyronine (T3, Cytomel) with
      sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI) in the treatment of MDD.
      The focus will be on two overlapping populations: 1) those with evidence of HPT
      abnormalities, and 2) those who did not respond to a previous adequate SSRI trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1996</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>sertraline + triiodothyronine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sertraline + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triiodothyronine</intervention_name>
    <arm_group_label>sertraline + triiodothyronine</arm_group_label>
    <other_name>Cytomel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sertraline + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <arm_group_label>sertraline + triiodothyronine</arm_group_label>
    <arm_group_label>sertraline + placebo</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the ages of 18 and 60. (The upper age is limited to 60 because
             thyroid changes, including blunting of the TSH response to TRH occurs with age and can
             potentially confound the relationship between the HPT axis and MDD.)

          -  Primary diagnosis of unipolar Major Depressive Disorder

          -  HAM-D (21 item) score &gt;18

        Exclusion Criteria:

          -  Alcohol abuse or alcohol dependence within the past year.

          -  Psychoactive substance abuse or dependence within the past year.

          -  Clinical evidence of severe Personality Disorder that would make study participation
             and completion unlikely.

          -  ECT within the past 6 months.

          -  Grade I hypothyroidism defined as low thyroid hormone levels with an associated
             elevated TSH; hyperthyroidism defined as elevated thyroid hormone concentrations with
             a low TSH.

          -  Serious and unstable medical illnesses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boadie W Dunlop, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res. 2012 Nov;46(11):1406-13. doi: 10.1016/j.jpsychires.2012.08.009. Epub 2012 Sep 7.</citation>
    <PMID>22964160</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Boadie W. Dunlop</investigator_full_name>
    <investigator_title>Director, Mood and Anxiety Disorders Program</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Mental Health</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

